Alpha-methyltryptamine (AMT) is a tryptamine derivative and shares many pharmacological similarities with those of schedule I hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, psilocybin, and LSD. Since 1999, there has been a growing popularity of AMT among drug abusers for its hallucinogenic-like effects. In the 1960s, following extensive clinical studies on AMT as a possible antidepressant drug, the Upjohn Company concluded that AMT was a toxic substance and produces psychosis.

AMT has no approved medical uses in the United States.

AMT is a tryptamine (indoleethylamine) derivative. The hydrochloride salt of AMT is a white crystalline powder. AMT, similar to several other schedule I hallucinogens, binds with moderate affinities to serotonin (5-HT) receptors (5-HT1 and 5-HT2). AMT inhibits the uptake of monoamines especially 5-HT and is a potent inhibitor of monoamine oxidase (MAO) (especially MAO-A), an enzyme critical for the metabolic degradation of monoamines, the brain chemicals important for sensory, emotional and other behavioral functions. AMT has been shown to produce locomotor stimulant effects in animals. It has been hypothesized that both 5-HT and dopamine systems mediate the stimulant effects of AMT. In animals, AMT produces behavioral effects that are substantially similar to those of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and methylene- dioxymethamphetamine (MDMA), both schedule I hallucinogens, in animals.

In humans, AMT elicits subjective effects including hallucinations. It has an onset of action of about 3 to 4 hours and duration of about 12 to 24 hours, but may produce an extended duration of 2 days in some subjects. Subjects report uncomfortable feelings, muscular tension, nervous tension, irritability, restlessness, unsettled feeling in stomach, and the inability to relax and sleep. AMT can alter sensory perception and judgment and can pose serious health risks to the user and the general public. Abuse of AMT led to two emergency department admissions and one death. AMT increases blood pressure and heart rate and dilates pupils, causes deep tendon reflexes and impairs coordination.

AMT is abused for its hallucinogenic effects and is used as substitute for MDMA. It is often administered orally as either powder or capsules at doses ranging from 15-40 mg. Other routes of administration include smoking and snorting.

Youth and young adults are the main abusers of AMT. Internet websites are a source that high school students and United States soldiers have used to obtain and abuse AMT.

According to the System to Retrieve Information from Drug Evidence (STRIDE) data, first recorded submission by law enforcement to DEA laboratories of a drug exhibit containing AMT occurred in 1999. During 1999 to 2006, DEA forensic laboratories analyzed 38 drug exhibits from 16 different law enforcement cases pertaining to the trafficking, distribution and abuse of AMT. The analyzed drug exhibits comprised of 21 capsules and 1,014.36 grams of powder. There were 4 cases with 6 exhibits, and 7 cases with 19 exhibits in 2002 and 2003, respectively. Following federal control of AMT as a schedule I substance in 2003, number of AMT encounters by law enforcement as reported in STRIDE decreased to 2 cases with 5 exhibits, and 1 case with 1 exhibit in 2004 and 2005, respectively. In 2006, no cases were recorded in the STRIDE system.

According to the National Forensic Laboratory Information System (NFLIS), state and local forensic laboratories analyzed 19 AMT drug items from 16 different law enforcement cases during 1999 through 2006. According to the STRIDE and NFLIS, AMT has been encountered in a number of states including Alabama, Alaska, Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Illinois, Indiana, Kentucky, Maryland, Minnesota, Missouri, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Pennsylvania, Texas, Virginia, and Wisconsin. AMT has been illicitly available from United States and foreign chemical companies and from Internet websites. Additionally, there is evidence of attempted clandestine production of AMT.

The Drug Enforcement Administration (DEA) placed AMT temporarily in schedule I of the Controlled Substances Act (CSA) on April 4, 2003, pursuant to the temporary scheduling provisions of the CSA (68 FR 16427). On September 29, 2004, AMT was controlled as a schedule I substance under the CSA (69 FR 58050).